The InVivoPro Anti-Mouse PD-L1 (B7-H1, CD274) in vivo antibody, Clone 10F.9G2 is a cutting-edge tool for preclinical cancer immunotherapy research, designed to block the PD-1/PD-L1 immune checkpoint pathway with high specificity and efficacy. Developed by BioXCell, this monoclonal antibody targets murine PD-L1 (CD274), a cell surface ligand that mediates immune evasion in tumors by binding to PD-1 on T cells .
Clone 10F.9G2 is derived from a rat IgG2b clone, produced in animal-free facilities, and undergoes rigorous quality control to ensure ultra-low endotoxin levels (<2 EU/mg) and high purity (>95%) . It specifically binds to the extracellular domain of mouse PD-L1, preventing its interaction with PD-1 and B7-1 (CD80), thereby restoring T-cell proliferation, cytokine production (e.g., IFN-γ, TNF-α), and cytotoxic activity against tumor cells . In murine models of melanoma and colon cancer, 10F.9G2 has demonstrated robust reversal of immune suppression, leading to significant tumor regression and prolonged survival .
While PD-L1’s role in autoimmunity is less explored, 10F.9G2 has been used to study PD-L1-mediated immune tolerance in models of experimental colitis and graft-versus-host disease (GVHD). In GVHD models, 10F.9G2 reduced T-cell activation and inflammation by blocking PD-L1 interactions with PD-1 .
In murine transplant models, 10F.9G2 prevents allograft rejection by modulating T-cell responses, offering insights into immune tolerance mechanisms .
10F.9G2’s binding specificity and functional activity are validated by flow cytometry, ELISA, and immunohistochemistry, showing strong reactivity to PD-L1-expressing murine T cells and tumor cells . Pharmacokinetic studies in BALB/c mice reveal a linear dose-response profile, with a half-life of ~6–8 days following intraperitoneal administration . A typical dosing regimen involves 2.5–5 mg/kg intraperitoneally twice weekly, depending on the tumor model .
The InVivoPro Anti-Mouse PD-L1 (B7-H1, CD274) antibody, Clone 10F.9G2 is a versatile and validated tool for preclinical research, supporting advancements in cancer immunotherapy, autoimmune disease modeling, and transplantation studies. Its high specificity, low endotoxin levels, and proven efficacy in combination therapies position it as a gold standard for PD-L1 pathway blockade in murine models.
Figure 1: Mechanism of Action of 10F.9G2
Caption: 10F.9G2 blocks PD-L1/PD-1 interactions, 解除 T-cell inhibition, and restores antitumor immunity. (A) In untreated tumors, PD-L1 on cancer cells binds PD-1 on T cells, suppressing T-cell activation. (B) 10F.9G2 binding to PD-L1 prevents ligand interaction, enabling T-cell proliferation and cytokine secretion.
Figure 2: Efficacy of 10F.9G2 in a Murine Colon Cancer Model
Caption: Treatment with 10F.9G2 (5 mg/kg, IP twice weekly) significantly reduces tumor volume compared to isotype control in CT26 colon cancer mice. Data adapted from .
Figure 3: Flow Cytometry Validation of 10F.9G2 Binding
Caption: 10F.9G2 (solid line) specifically stains PD-L1+ tumor cells from mouse splenocytes, while isotype control (dashed line) shows minimal background. Data adapted from .
References
The InVivoPro Anti-Mouse CD4 in vivo antibody, Clone GK1.5 is a cornerstone tool in preclinical immunology research, enabling precise depletion of CD4⁺ T cells to study their role in immune responses. Developed by BioXCell, this monoclonal antibody target
The InVivoPro Anti-Mouse PD-L1 (B7-H1, CD274) in vivo antibody, Clone 10F.9G2 is a cutting-edge tool for preclinical cancer immunotherapy research, designed to block the PD-1/PD-L1 immune checkpoint pathway with high specificity and efficacy. Developed by
The InVivoPro Anti-Mouse PD-1 (CD279) in vivo antibody, Clone RMP1-14 has emerged as a pivotal tool in preclinical cancer immunotherapy research, enabling robust blockade of the PD-1/PD-L1 immune checkpoint pathway. This high-specificity monoclonal antibo
© 2021-2025 InvivoCrown Limited. All rights reserved.